


UNITED STATES DISTRICT COURT
DISTRICT OF MASSACHUSETTS
OFFICE OF THE CLERK
1 COURTHOUSE WAY
BOSTON, MASSACHUSETTS 02210

Sarah Allison Thornton CLERK OF COURT

Mr. Larry Baerman, Clerk United States District Court 225 Federal Bldg 15 Henry Street Binghamton, NY 13901



August 18, 2005

IN RE: MOL DOCKET No. 1456 In Re: Pharmaceutical Industry Average Wholesale Price Litigation

USDC - Massachusetts <u>Lead</u> Case No. 1:01CV12257-PBS Your Case: Civil Action No: 7:05-cv-00715 The County of Jefferson v. Abbott Laboratories, Inc. et al District of MA No: 1:05-cv-11704 PBS

Dear Mr. Baerman:

Enclosed is a certified copy of the Order of the Judicial Panel on Multi-District Litigation, transferring the cases on the attached listing to the U.S. District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to Title 28 United States Code Section 1407. These cases have been assigned to the Honorable Patti B. Saris.

In accordance with the Rules concerning Multi-District Litigation, please forward the original case file, along with a certified copy of the docket entries and a copy of the transfer order for the case now pending in your district as indicated above. Also include a copy of this letter when transmitting your records to the above address.

Your prompt attention to this matter is greatly appreciated. If you should have any questions, please do not hesitate to contact the undersigned at 617-748-9113, Robert Alba, Courtroom Clerk for Judge Saris at 617-748-9175 or Christine Patch, Docket Clerk for Judge Saris, at 617-748-9178.

Sincerely,

Kimberly M. Abaid Deputy Clerk

mberly H. avaic

Information Copy to:

Michael Beck, Clerk of the Panel

Counsel of Record Robert Alba Christine Patch

12/13/05

that the foregoing doctorary Mas and correct copy of the electronic doctorary files and correct copy of the electronically flest original files on control files in my stilles by College Court S. District of Massachuse

JUDICIAL PANEL ON MULTIDISTRICT LITIGATION

JUL 26 2005

DOCKET NO. 1456

FILED OFFICE FILED CLERK'S OFFICE

OF MASS

IN RE PHARMACEUTICAL INDUSTRY AVERAGE WHOLESALE PRICE LITIGATION

The County of Madison v. Abbott Laboratories, Inc., et al., N.D. New York, C.A. No. 5:05-714

County of Jefferson v. Abbott Laboratories, Inc., et al., N.D. New York, C.A. No. 7:05-715

CONDITIONAL TRANSFER ORDER (CTO-24)

On April 30, 2002, the Panel transferred 16 civil actions to the United States District Court for the District of Massachusetts for coordinated or consolidated pretrial proceedings pursuant to 28 U.S.C. § 1407. Since that time, 58 additional actions have been transferred to the District of Massachusetts. With the consent of that court, all such actions have been assigned to the Honorable Patti B. Saris.

It appears that the actions on this conditional transfer order involve questions of fact which are common to the actions previously transferred to the District of Massachusetts and assigned to Judge Saris.

Pursuant to Rule 7.4 of the Rules of Procedure of the Judicial Panel on Multidistrict Litigation, 199 F.R.D. 425, 435-36 (2001), these actions are transferred under 28 U.S.C. § 1407 to the District of Massachusetts for the reasons stated in the order of April 30, 2002, 201 F.Supp.2d 1378 (J.P.M.L. 2002), and, with the consent of that court, assigned to the Honorable Patti B. Saris.

This order does not become effective until it is filed in the Office of the Clerk of the United States District Court for the District of Massachusetts. The transmittal of this order to said Clerk shall be stayed fifteen (15) days from the entry thereof and if any party files a notice of opposition with the Clerk of the Panel within this fifteen (15) day period, the stay will be continued until further order of the Panel.

Inasmuch as no objection is pending at this time, the stay is lifted.

AUG 11 2005

CLERK'S OFFICE
JUDICIAL PANEL ON
MULTIDISTRICT LITIGATION

FOR THE PANEL:

Michael J. Beck Clerk of the Panel

CLOSED

U.S. District Court Northern District of New York [LIVE - Version 2.5] (Syracuse) CIVIL DOCKET FOR CASE #: 5:05-cv-00714-NAM-DEP Internal Use Only

The County of Madison v. Abbott Laboratories, Inc. et al Assigned to: Judge Norman A. Mordue Referred to: Magistrate Judge David E. Peebles Cause: 42:1396 - Tort Negligence Date Filed: 06/08/2005
Jury Demand: Plaintiff
Nature of Suit: 890 Other Statutory Actions
Jurisdiction: Federal Question

Plaintiff

The County of Madison

represented by Aaron D. Hovan

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600 Fax: 212-751-2540 Email: ahovan@kmslaw.com LEAD ATTORNEY ATTORNEY TO BE NOTICED

Joanne M. Cicala

The man policy

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600 Fax: 212-751-2540 Email: jcicala@kmslaw.com LEAD ATTORNEY ATTORNEY TO BE NOTICED

Roger W. Kirby

Kirby, McInerney Law Firm 830 Third Avenue New York, NY 10022 212-371-6600 Fax: 212-751-2540 Email: iramirez@kmslaw.com LEAD ATTORNEY ATTORNEY TO BE NOTICED

V.

Defendant

Abbott Laboratories, Inc.

Defendant

Agouron Pharmaceuticals, Inc.

Defendant

Alcon Laboratories, Inc.

Defendant

Allergan, Inc.

Defendant

Alpharma, Inc.

Defendant

Amgen, Inc.

<u>Defendant</u>
Andrx Corp.
Defendant Astrazeneca Pharmaceuticals L.P.
Defendant
Aventis Pharmaceuticals, Inc.
<u>Defendant</u>
Barr Laboratories, Inc.
<u>Defendant</u>
Bayer Corp.
Defendant Ben Venue Laboratories, Inc.
Defendant
Biogen Idec, Inc.
<u>Defendant</u>
Biovail Pharmaceuticals, Inc.
<u>Defendant</u>
Boehringer Ingelheim Corp.
<u>Defendant</u> Boehringer Ingelheim Pharmaceuticals, Inc.
Doen inger ingeneim i nar maceuteais, inc.
Defendant
Defendant Bristol-Meyers Squibb Company
Bristol-Meyers Squibb Company
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc.
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc.
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company Defendant Endo Pharmaceuticals, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company Defendant Endo Pharmaceuticals, Inc. Defendant Ethex Corp.
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company Defendant Endo Pharmaceuticals, Inc. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company Defendant Endo Pharmaceuticals, Inc. Defendant Ethex Corp. Defendant
Bristol-Meyers Squibb Company Defendant Dermik Laboratories, Inc. Defendant Dey, Inc. Defendant Eisai, Inc. Defendant Eli Lilly and Company Defendant Endo Pharmaceuticals, Inc. Defendant Ethex Corp. Defendant Forest Laboratories, Inc.

<u>Defendant</u> Fujisawa Healthcare, Inc.	
Defendant	
Fujisawa USA, Inc.	
<u>Defendant</u>	
Genentech, Inc.	
Defendant	
Genzyme Corp.	
Defendant Glaxosmithkline, P.L.C.	
Defendant	
Greenstone, Ltd.	
Defendant	
Hoffman-La Roche, Inc.	
<u>Defendant</u>	
Immunex Corp.	
<u>Defendant</u> Ivax Corp.	
<u>Defendant</u>	
Ivax Pharmaceuticals, Inc.	
<u>Defendant</u>	
Janssen Pharmaceutica Products, LP	
<u>Defendant</u> Johnson & Johnson	
Defendant	
King Pharmaceuticals	
<u>Defendant</u>	
McNeil-PPC, Inc.	
<u>Defendant</u> Medimmune, Inc.	
<u>Defendant</u> Merck & Co., Inc.	
<u>Defendant</u>	

Monarch Pharmaceuticals, Inc.

Mylan Laboratories, Inc.

Mylan Pharmaceuticals, Inc.

Defendant

Defendant

efe		

Novartis Pharmaceuticals Corp.

Defendant

Novo Nordisk Pharmaceuticals, Inc.

Defendant

Oncology Therapeutics Network Corp.

Defendant

Organon Pharmaceuticals USA, Inc.

Defendant

Ortho Biotech Products LP

Defendant

Ortho-McNeil Pharmaceutical, Inc.

Defendant

Par Pharmaceutical, Inc.

Defendant

Pfizer, Inc.

Defendant

Pharmacia Corp.

Defendant

Purdue Pharma, L.P.

<u>Defendant</u>

Purepac Pharmaceutical Co.

<u>Defendant</u>

Reliant Pharmaceuticals

Defendant

Roche Laboratories, Inc.

Defendant

Roxane Laboratories, Inc.

Defendant

Sandoz, Inc.

Defendant

Sanofi-Synthelabo, Inc.

Defendant

Schering Corp.

Defendant

Schering-Plough Corp.

Defendant

Serono, Inc.

Defendant

Smithklinebeecham Corp.

doing business as Glaxosmithkline

Defendant

Takeda Pharmaceuticals North America, Inc.

Defendant

Tap Pharmaceutical Products, Inc.

Defendant

Teva Pharmaceutical USA, Inc.

Defendant

UCB Pharma, Inc.

Defendant

UDL Laboratories, Inc.

Defendant

Warrick Pharmaceuticals Corp.

Defendant

Watson Pharma, Inc.

Defendant

Watson Pharmaceuticals, Inc.

Defendant

Wyeth

Date Filed	#	Docket Text
06/08/2005	● 1	COMPLAINT against Alcon Laboratories, Inc., Allergan, Inc., Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Bayer Corp., Ben Venue Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa USA, Inc., Genentech, Inc., Forest Pharmaceuticals, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, L.P., Johnson & Johnson, King Pharmaceuticals, McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products L.P., Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sandof. Synthelabo, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Warrick Pharmaceuticals Corp., Watson Pharma, Inc., Watson Pharmaceuticals, Inc., Wyeth, Abbott Laboratories, Inc., Agouron Pharmaceuticals, Inc. (Filing fee \$ 250 receipt number ALB000911) filed by The County of Madison. (Attachments: # 1 Exhibit(s) A# 2 Exhibit(s) B# 3 Exhibit(s) C# 4 Exhibit(s) D# 5 Exhibit(s) E)(ban) (Entered: 06/09/2005)
06/08/2005	•	Summons Issued as to Alcon Laboratories, Inc., Allergan, Inc., Alpharma, Inc., Amgen, Inc., Andrx Corp., Astrazeneca Pharmaceuticals L.P., Aventis Pharmaceuticals, Inc., Barr Laboratories, Inc., Bayer Corp., Ben Venue Laboratories, Inc., Biogen Idec, Inc., Biovail Pharmaceuticals, Inc., Boehringer Ingelheim Corp., Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Meyers Squibb

		Company, Dermik Laboratories, Inc., Dey, Inc., Eisai, Inc., Eli Lilly and Company, Endo Pharmaceuticals, Inc., Ethex Corp., Forest Laboratories, Inc., Forest Pharmaceuticals, Inc., Fujisawa Healthcare, Inc., Fujisawa USA, Inc., Genentech, Inc., Genzyme Corp., Glaxosmithkline, P.L.C., Greenstone, Ltd., Hoffman-La Roche, Inc., Immunex Corp., Ivax Corp., Ivax Pharmaceuticals, Inc., Janssen Pharmaceutica Products, LP, Johnson & Johnson, King Pharmaceuticals, McNeil-PPC, Inc., Medimmune, Inc., Merck & Co., Inc., Monarch Pharmaceuticals, Inc., Mylan Laboratories, Inc., Mylan Pharmaceuticals, Inc., Novartis Pharmaceuticals Corp., Novo Nordisk Pharmaceuticals, Inc., Oncology Therapeutics Network Corp., Organon Pharmaceuticals USA, Inc., Ortho Biotech Products LP, Ortho-McNeil Pharmaceutical, Inc., Par Pharmaceutical, Inc., Pfizer, Inc., Pharmacia Corp., Purdue Pharma, L.P., Purepac Pharmaceutical Co., Reliant Pharmaceuticals, Roche Laboratories, Inc., Roxane Laboratories, Inc., Sandoz, Inc., Sanofi-Synthelabo, Inc., Schering Corp., Schering-Plough Corp., Serono, Inc., Smithklinebeecham Corp., Takeda Pharmaceuticals North America, Inc., Tap Pharmaceutical Products, Inc., Teva Pharmaceutical USA, Inc., UCB Pharma, Inc., UDL Laboratories, Inc., Warrick Pharmaceuticals Corp., Watson Pharma, Inc., Watson Pharmaceuticals, Inc., Wyeth, Abbott Laboratories, Inc., Agouron Pharmaceuticals, Inc., (ban) (Entered: 06/09/2005)
06/08/2005	<u>2</u> 2	G.O. 25 FILING ORDER ISSUED Initial Conference set for 10/6/2005 10:30 AM in Syracuse before Magistrate Judge David E. Peebles. Civil Case Management Plan due by 9/26/2005. (ban) (Entered: 06/09/2005)
07/29/2005	3 3	NOTICE advising of Conditional transfer order by MDL; Case styed pending further notice (kcl,) (Entered: 08/01/2005)
08/11/2005	3	NOTICE to plaintiff's counsel that the Rule 16 Conference scheduled for 10/6/05 at 10:30 AM in Syracuse before Judge Peebles has been canceled. This case has been stayed per the conditional transfer notice filed w/ this court3 which states that this case will soon be transferred to the MDL. Case will remain open until the transfer order is filed w/ this court. (sal,) (Entered: 08/11/2005)
12/13/2005	$\mathfrak{D}_{\underline{4}}$	NOTICE from Judicial Panel on MDL advsing the Clerk of the District of MA that the 15 day stay period has passed; The transferee clerk shall submit a certified copy of the transfer Order to the Transferor Court (kcl,) (Entered: 12/13/2005)
12/13/2005	3 <u>5</u>	MDL ORDER TRANSFERRING CASE to District of Massachusetts; Clerk sent Certified copy of docket sheet and transferring order (kcl,) (Entered: 12/13/2005)